HIV-1 virologic and immunologic progression and initiation of antiretroviral therapy among HIV-1-infected subjects in a trial of the efficacy of recombinant glycoprotein 120 vaccine

Journal of Infectious Diseases

Volumn 192, Issue 6, 2005, Pages 974-983

  Gilbert, Peter B ^a   Ackers, Marta L ^b   Berman, Phillip W ^c   Francis, Donald P ^c   Popovic, Vladimir ^f   Hu, Dale J ^b   Heyward, William L ^e   Sinangil, Faruk ^d   Shepherd, Bryan E ^a   Gurwith, Marc ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Global Solutions for Infectious Diseases   (United States)

^d VaxGen Inc   (United States)

^e Quattro Clinical Research   (United States)

^f Janssen Ortho Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; RECOMBINANT GLYCOPROTEIN GP 120; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTICENTER STUDY; NETHERLANDS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; UNITED STATES; VACCINATION; VIRUS LOAD;

ADOLESCENT; ADULT; AIDS VACCINES; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PLACEBOS; RNA, VIRAL;

EID: 24644479045     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/432734     Document Type: Article

References (54)

1. Harro CD, Judson FN, Gorse GJ, et al. Recruitment and baseline epidemiologic profile of participants in the first phase 3 HIV vaccine efficacy trial. J Acquir Immune Defic Syndr 2004; 37:1385-92.
2. Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S325-31.
3. rgp120 HIV Vaccine Study Group. Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection. J Infect Dis 2005; 191:654-65.
4. Margolick JB, Farzadegan H, Hoover DR, Saah AJ. Relationship between infectious cell-associated human immunodeficiency virus type 1 load, T lymphocyte subsets, and stage of infection in homosexual men. J Infect Dis 1996; 173:468-71.
5. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996; 335:1091-8.
6. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
7. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996; 276:105-10.
8. HIV-1 Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. AIDS Res Hum Retroviruses 2000; 16:1123-33.
9. Lyles RH, Munoz A, Yamashita TE, et al. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. J Infect Dis 2000; 181:872-80.
10. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
11. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179:717-20.
12. Centers for Disease Control and Prevention. Update: AIDS-United States, 2000. MMWR Morb Mortal Wkly Rep 2002; 51:592-5.
13. Gilbert PB, DeGruttola V, Hammer SM, Kuritzkes DR. Virologic and regimen termination surrogate end points in AIDS clinical trials. JAMA 2001; 285:777-84.
14. Gilbert PB, DeGruttola VG, Hudgens MG, Self SG, Hammer S, Corey L. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials. J Infect Dis 2003; 188:179-93.
15. Hudgens MG, Hoering A, Self SG. On the analysis of viral load end points in HIV-1 vaccine trials. Stat Med 2003; 22:2281-98.
16. Nabel GJ. Challenges and opportunities for development of an AIDS vaccine. Nature 2001; 410:1002-7.
17. Graham BS. Clinical trials of HIV-1 vaccines. Ann Rev Med 2002; 53: 207-21.
18. Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-92.
19. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
20. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106:539-49.
21. Shiver JW, Fu T-M, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 2002; 415:331-5.
22. Israel ZR, Edmonson PF, Maul DH, et al. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994; 68:1843-53.
23. Voss G, Manson K, Montefiori D, et al. Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine. J Virol 2003; 77:1049-58.
24. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1991.
25. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342:921-9.
26. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1 discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-53.
27. Stover J, Walker N, Garnett GP, et al. Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet 2002; 360:73-7.
28. Berman PW. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S277-89.
29. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-9.
30. Barouch DH, Kunstman J, Glowczwskie J, et al. Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003; 77:7367-75.
31. Lukashov VV, Goudsmit J, Paxton WA. The genetic diversity of HIV-1 and its implications for vaccine development. In: Wong-Staal F, Gallo RC, eds. AIDS vaccine research. New York: Marcel Dekker, 2002:93-120.
32. Cai T, Gilbert PB, Self SG. Cox model inferences on relative risks linked in two stages [technical report]. Cambridge, MA: Harvard University, 2004.
33. Panel on clinical practices for treatment of HIV-1 infection. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/ guidelines/. Accessed 29 July 2005.
34. Liang KY, Zeger SL. Longitudinal data analysis using the generalized linear models. Biometrika 1986; 73:13-22.
35. Clements-Mann ML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses 1998; 14(Suppl 3):S197-203.
36. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Biological and virologic characteristics of primary HIV-1 infection. Ann Int Med 1998; 128:613-20.
37. Hu DJ, Vanichseni S, Mastro TD, et al. Viral load differences in early infection with two HIV-1 subtypes. AIDS 2001; 15:683-91.
38. Sterling TR, Vlahov D, Astemborski J, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001; 344:720-5.
39. Shepherd BE, Gilbert PB, Jemiai Y, Rotnitzky AR. Sensitivity analyses comparing outcomes only exisitng in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials. Biometrika (in press).
40. Hughes JP. Mixed effects models with censored data and application to HIV RNA levels. Biometrics 1999; 55:625-9.
41. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41(RR-17):1-19.
42. Robinson WE, Montefiori DC, Mitchell WM. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1988; 1:790-4.
43. Takeda A, Tuazon CU, Ennis FA. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988; 242:580-3.
44. Homsy J, Meyer M, Levy JA. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol 1990; 64:1437-40.
45. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40:444-51.
46. Burke DS. Human HIV vaccine trials: does antibody-dependent enhancement pose a genuine risk? Perspect Biol Med 1992; 35:511-30.
47. Mascola JR, Mathieson BJ, Zack PM, Walker MC, Halstead SB, Burke DS. Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials. AIDS Res Hum Retroviruses 1993; 9:1175-84.
48. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 1994; 19:500-12.
49. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003; 9:1209-13.
50. Porter DD, Larson AE, Porter HG. The pathogenesis of Aleutian disease of mink. II. Enhancement of tissue lesions following the administration of a killed virus vaccine or passive antibody. J Immunol 1972; 109:1-7.
51. Siebelink KH, Tijhaar E, Huisman RC, et al. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 1995; 69:3704-11.
52. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995; 333:450-1.
53. World Health Organization. Scaling up antiretroviral therapy in resource limited settings: guidelines for a public health approach, executive summary, April 2002. Available at: http://www.who.int/HIV_AIDS/first.html. Accessed 1 September 2004.
54. Morgan D, Mahe C, Mayania B, Whitworth JA. Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. Brit Med J 2002; 324:193-6.